Overview
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Eligibility
Inclusion Criteria:
- Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
- Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy
Exclusion Criteria:
• Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g.,
ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during
pregnancy or just prior to pregnancy